Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Dose Escalation and Cohort Expansion Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and and Efficacy of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

NCT06224855 is registered in ClinicalTrials.gov with Hangzhou DAC Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06224855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06224855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Dose Escalation and Cohort Expansion Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and and Efficacy of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Lead sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 24, 2024
Completion date
December 31, 2027
Enrollment
280 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, hematological malignancies